BACKGROUND: In many countries, ovarian cancer is the most lethal gynecological malignancy. Its poor prognosis is mainly due to the late stage of disease with metastasis at presentation. The significant failure rate of chemotherapy in patients with advanced stage disease is also a main concern. As such, developing novel therapeutic targets is essential to improve long-term survival. Overexpression of Tropomyosin-related kinase B (TrkB), a tyrosine kinase receptor, has been documented in ovarian cancer and is found to be correlated with poor prognosis. OBJECTIVE/ METHODS: We discuss the functional roles and the related downstream signaling pathways of TrkB and its ligand brain-derived neurotrophic factor (BDNF) in ovarian cancer. The possible crosstalk between TrkB/BDNF and other putative molecular targets in ovarian cancer is also discussed. RESULTS/ CONCLUSIONS: All these latest findings shed light on the application of TrkB as a therapeutic target for ovarian cancer.
BACKGROUND: In many countries, ovarian cancer is the most lethal gynecological malignancy. Its poor prognosis is mainly due to the late stage of disease with metastasis at presentation. The significant failure rate of chemotherapy in patients with advanced stage disease is also a main concern. As such, developing novel therapeutic targets is essential to improve long-term survival. Overexpression of Tropomyosin-related kinase B (TrkB), a tyrosine kinase receptor, has been documented in ovarian cancer and is found to be correlated with poor prognosis. OBJECTIVE/ METHODS: We discuss the functional roles and the related downstream signaling pathways of TrkB and its ligand brain-derived neurotrophic factor (BDNF) in ovarian cancer. The possible crosstalk between TrkB/BDNF and other putative molecular targets in ovarian cancer is also discussed. RESULTS/ CONCLUSIONS: All these latest findings shed light on the application of TrkB as a therapeutic target for ovarian cancer.
Authors: Mohammad Malekan; Sasan Salehi Nezamabadi; Elham Samami; Mehdi Mohebalizadeh; Amene Saghazadeh; Nima Rezaei Journal: J Cancer Res Clin Oncol Date: 2022-09-29 Impact factor: 4.322
Authors: Diana M Cittelly; Irina Dimitrova; Erin N Howe; Dawn R Cochrane; Annie Jean; Nicole S Spoelstra; Miriam D Post; Xian Lu; Russell R Broaddus; Monique A Spillman; Jennifer K Richer Journal: Mol Cancer Ther Date: 2012-10-16 Impact factor: 6.261
Authors: Lisa A Cannon-Albright; Craig C Teerlink; James M Farnham; Alun W Thomas; John J Zone; Sancy A Leachman Journal: J Invest Dermatol Date: 2012-09-06 Impact factor: 8.551
Authors: J Saadi Imam; Jason R Plyler; Hima Bansal; Suresh Prajapati; Sanjay Bansal; Jennifer Rebeles; Hung-I Harry Chen; Yao-Fu Chang; Subbarayalu Panneerdoss; Behyar Zoghi; Kalyan C Buddavarapu; Russell Broaddus; Peter Hornsby; Gail Tomlinson; Jeffrey Dome; Ratna K Vadlamudi; Alexander Pertsemlidis; Yidong Chen; Manjeet K Rao Journal: PLoS One Date: 2012-12-21 Impact factor: 3.240